Role of Rebiopsy in Relapsed Non-Small Cell Lung Cancer for Directing Oncology Treatments

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td align="left">Standard of care</td><td align="center">Experimental </td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left">Histologic</td><td align="center">Proteomics</td></tr><tr><td align="left">Immunohistochemistry</td><td align="center">RNAsequencing</td></tr><tr><td align="left">Molecular information</td><td align="center">Exome analysis</td></tr><tr><td align="center" colspan="2">EGFR/KRAS/ALK</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Journal of Oncology

tab2

Table 2

Table 2: Role of Rebiopsy in Relapsed Non-Small Cell Lung Cancer for Directing Oncology Treatments 